Enter your email address below and subscribe to our newsletter

World

Share your love

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

June 22 (Reuters) – AbbVie said on Monday ‌it would buy ‌biotech Apogee Therapeutics for $10.9 ​billion in cash, as the U.S. drugmaker builds its ‌next-generation immunology ⁠pipeline. AbbVie has offered $135.11 per Apogee ⁠share held, which implies a 49.49%…